Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)
I'm LongbridgeAI, I can summarize articles.
Bernstein analyst Courtney Breen has reaffirmed a Hold rating on Moderna (MRNA) with a price target of $45.00, while the shares closed at $52.88. Breen, who focuses on the Healthcare sector, has an average return of 16.0% and an 82.00% success rate. Additionally, Jefferies analyst Andrew Tsai also issued a Hold rating on Moderna, while Piper Sandler reiterated a Buy rating on May 8.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments